261 related articles for article (PubMed ID: 32168782)
21. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.
McCune K; Mehta R; Thorat MA; Badve S; Nakshatri H
Oncol Rep; 2010 Nov; 24(5):1233-9. PubMed ID: 20878115
[TBL] [Abstract][Full Text] [Related]
22. FOXA1 in breast cancer.
Nakshatri H; Badve S
Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
24. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells.
Laganière J; Deblois G; Giguère V
Mol Endocrinol; 2005 Jun; 19(6):1584-92. PubMed ID: 15831516
[TBL] [Abstract][Full Text] [Related]
25. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells.
Need EF; Selth LA; Harris TJ; Birrell SN; Tilley WD; Buchanan G
Mol Endocrinol; 2012 Nov; 26(11):1941-52. PubMed ID: 23023562
[TBL] [Abstract][Full Text] [Related]
26. Effect of estrogen receptor α binding on functional DNA methylation in breast cancer.
Ung M; Ma X; Johnson KC; Christensen BC; Cheng C
Epigenetics; 2014 Apr; 9(4):523-32. PubMed ID: 24434785
[TBL] [Abstract][Full Text] [Related]
27. Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.
Cornelissen LM; Henneman L; Drenth AP; Schut E; de Bruijn R; Klarenbeek S; Zwart W; Jonkers J
J Mammary Gland Biol Neoplasia; 2019 Dec; 24(4):305-321. PubMed ID: 31729597
[TBL] [Abstract][Full Text] [Related]
28. Luminal lncRNAs Regulation by ERα-Controlled Enhancers in a Ligand-Independent Manner in Breast Cancer Cells.
Miano V; Ferrero G; Rosti V; Manitta E; Elhasnaoui J; Basile G; De Bortoli M
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462945
[TBL] [Abstract][Full Text] [Related]
29. ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer.
Lin CL; Tan X; Chen M; Kusi M; Hung CN; Chou CW; Hsu YT; Wang CM; Kirma N; Chen CL; Lin CH; Lathrop KI; Elledge R; Kaklamani VG; Mitsuya K; Huang TH
BMC Med Genomics; 2020 May; 13(1):69. PubMed ID: 32408897
[TBL] [Abstract][Full Text] [Related]
30. PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.
Magnani L; Ballantyne EB; Zhang X; Lupien M
PLoS Genet; 2011 Nov; 7(11):e1002368. PubMed ID: 22125492
[TBL] [Abstract][Full Text] [Related]
31. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
[TBL] [Abstract][Full Text] [Related]
32. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.
Bernardo GM; Lozada KL; Miedler JD; Harburg G; Hewitt SC; Mosley JD; Godwin AK; Korach KS; Visvader JE; Kaestner KH; Abdul-Karim FW; Montano MM; Keri RA
Development; 2010 Jun; 137(12):2045-54. PubMed ID: 20501593
[TBL] [Abstract][Full Text] [Related]
33. Estrogen induces dynamic ERα and RING1B recruitment to control gene and enhancer activities in luminal breast cancer.
Zhang Y; Chan HL; Garcia-Martinez L; Karl DL; Weich N; Slingerland JM; Verdun RE; Morey L
Sci Adv; 2020 Jun; 6(23):eaaz7249. PubMed ID: 32548262
[TBL] [Abstract][Full Text] [Related]
34. RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites.
Yamaga R; Ikeda K; Horie-Inoue K; Ouchi Y; Suzuki Y; Inoue S
Horm Cancer; 2013 Aug; 4(4):222-32. PubMed ID: 23526455
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
Severson TM; Nevedomskaya E; Peeters J; Kuilman T; Krijgsman O; van Rossum A; Droog M; Kim Y; Koornstra R; Beumer I; Glas AM; Peeper D; Wesseling J; Simon IM; Wessels L; Linn SC; Zwart W
Oncotarget; 2016 Jun; 7(23):33901-18. PubMed ID: 27129152
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells.
Lo R; Burgoon L; Macpherson L; Ahmed S; Matthews J
Biochim Biophys Acta; 2010; 1799(5-6):469-79. PubMed ID: 20079471
[TBL] [Abstract][Full Text] [Related]
37. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643
[TBL] [Abstract][Full Text] [Related]
38. Systematic identification of Ctr9 regulome in ERα-positive breast cancer.
Zeng H; Lu L; Chan NT; Horswill M; Ahlquist P; Zhong X; Xu W
BMC Genomics; 2016 Nov; 17(1):902. PubMed ID: 27829357
[TBL] [Abstract][Full Text] [Related]
39. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.
Wen W; Chen Z; Bao J; Long Q; Shu XO; Zheng W; Guo X
Nat Commun; 2021 Sep; 12(1):5318. PubMed ID: 34518541
[TBL] [Abstract][Full Text] [Related]
40. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.
Theodorou V; Stark R; Menon S; Carroll JS
Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
